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Intestinal Blood Flow, Gut Permeability, and Heart Failure*Benjamin Dicken, MBBS,y John G.F. Cleland, MDzSEE PAGE 1092F actors driving the progression of heart failure(HF) are diverse. Immunological and inﬂam-matory processes probably play an important
role in the pathogenesis and progression of HF (1,2).
Tumor necrosis factor, interleukin-1, interleukin-2,
interleukin-6, transforming growth factor, and
C-reactive protein are all elevated in patients with
HF. However, it is unclear whether the inﬂammatory
stimulus is driven by diseased myocardium; the acti-
vation of inﬂammatory pathways by factors, such as
galectin (3), derived from the heart, liver, or kidney;
low-grade infection of the respiratory, oropharyn-
geal, or gastrointestinal tract; or absorption of endo-
toxins from the gut (1,2,4).
The development of peripheral edema is a bad sign
in patients with HF (5), reﬂecting to varying degrees
increases in right atrial pressure, increased capillary
permeability, and reduced lymphatic drainage.
Although gravity may make ﬂuid accumulation most
obvious in dependent regions, venous congestion will
affect all circulations. However, the consequences
in some circulations may be more important than in
others. In some circulations, congestion may precip-
itate a vicious cycle accelerating the progression of
HF. Bowel wall edema alters gut permeability, which
may lead to changes in mucosal defenses and bacte-
rial ﬂora, increased bacterial translocation into the
circulation, and endotoxin absorption and increased*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the yDepartment of Cardiology, Castle Hill Hospital, Hull York
Medical School (at University of Hull), Kingston upon Hull, United
Kingdom; and the zNational Heart and Lung Institute, Imperial College,
London, United Kingdom. Both authors have received research funding
from Thermo Fisher Scientiﬁc, which manufactures the assay to measure
procalcitonin.cytokine production. Cytokine activation can, in turn,
provoke inﬂammation and ﬁbrosis and microvascular
and myocardial dysfunction. Niebauer et al. (6)
compared 20 patients who had chronic HF with
recent-onset peripheral edema with nonedematous
patients with chronic HF and healthy volunteers.
They measured blood markers of endotoxemia,
inﬂammation, and immune activation. Edematous
patients had higher plasma concentrations of endo-
toxin and several cytokines. After short-term diuretic
treatment, serum concentrations of endotoxin, but
not cytokines, fell. Interestingly, after patients had
been edema free for >3 months, endotoxin concen-
trations remained stable.
Brunkhorst et al. (2) showed that cardiogenic shock
was accompanied by pyrexia in patients surviving for
longer than 12 h. This phenomenon was associated
with a rise in plasma concentrations of procalcitonin,
a marker of infection. This might reﬂect increased gut
permeability and bacterial translocation due to bowel
wall congestion and/or ischemia.In this issue of the Journal, Sandek et al. (7)
investigate the relationship between intestinal blood
ﬂow, mucosal thickness, mucosal and fecal ﬂora,
gastrointestinal symptoms, and cachexia. They
demonstrate that intestinal blood ﬂow is reduced in
patients with HF and that patients with lower blood
ﬂow have higher serum concentrations of immuno-
globulin A–antilipopolysaccharide, which in turn are
correlated with increased growth of bacteria obtained
from biopsies of colonic mucosa but not stool bacte-
ria. The nature of the bacterial ﬂora also appeared to
be different from that in control subjects, perhaps
because of lower blood ﬂow and a more anaerobic
environment. Many cardiovascular drugs, including
diuretic agents and mineralocorticoid antagonists,
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biopsied are unlikely to reﬂect a truly normal healthy
population, so the ﬁndings should be interpreted
with caution. Lower intestinal blood ﬂow also was
associated with more gastrointestinal symptoms that
were thought to reﬂect altered bowel motility, more
HF severity, and the development of cachexia. An
increase in bowel wall thickness, thought to reﬂect
edema, also was observed, although this was not
related to blood ﬂow. Sandek et al. biopsied only the
large bowel wall, but there is evidence that the small
bowel is also affected. Arutyunov et al. (8) recruited
45 patients with chronic HF and compared them with
18 controls. Biopsies of the small intestine revealed
increased collagen content that was greatest in
patients with severe HF, especially those with
cachexia. Reduction in blood ﬂow may not just be due
to cardiac dysfunction and neuroendocrine activation
but also may reﬂect atherosclerotic disease, which is
prevalent in this population (9).
Cardiac cachexia has long been recognized as a
serious complication of advanced HF and an impor-
tant predictor of prognosis (10,11). Its precise inci-
dence and prevalence are difﬁcult to determine,
because there is no robust deﬁnition, and it often goes
unrecognized (12). These uncertainties make it difﬁ-
cult to understand the underlying mechanisms, but
proinﬂammatory cytokines, sympathetic nervous sys-
tem activation, insulin resistance, and old age are all
likely to play a role. Large clinical trials have demon-
strated an “obesity paradox,” suggesting that loss of
body weight is associated with an adverse outcome
long before a patient drops below what would usually
be considered a normal body weight (13,14). Mild to
moderate obesity is associated with a better prognosis
in patients with HF (13). Certainly for patients with
established chronic disease, not just cardiovascular
but pulmonary and renal, there is sufﬁcient evidence
to support the beneﬁts of larger body size, and this is
counterintuitive to the current concepts of ideal body
weight, particularly among the lay public (15).
Therapeutic interventions can provide circumstan-
tial evidence of important mechanisms underlying
cardiac cachexia. Beta-blockers improve the prognosis
of patients with HF, at least when left ventricularejection fraction is reduced and the patient is in sinus
rhythm. They also cause weight gain (16). This sug-
gests that sympathetic activation is an important
contributor to cardiac cachexia and might be one of
the mechanisms by which beta-blockers improve
outcomes. Insulin resistance might be improved by
exercise or pharmaceutically, although neither has
met with great success in improving prognosis (17,18).
Perhaps adipose tissue rather than muscle mass is the
more important protective component of obesity. A
series of studies in patients with HF suggested that the
administration of etanercept or inﬂiximab to block the
actions of tumor necrosis factor, thought to be an
important cytokine mediator of cachexia, was not
beneﬁcial and might have been harmful at higher
doses (19–21). The results might have been different if
only patients with marked cytokine activation had
been targeted. However, exactly why patients who
received these treatments tended to do worse on
average remains an unanswered concern.
Several large trials of long-term antibiotic therapy in
patients who have had myocardial infarctions have
been conducted. Overall, these studies showed that
long-term antibiotic therapy is safe but does not
reduce recurrent cardiac events or mortality in this
population (22–24). If gut bacteria play a role in the
progression of HF, then the simplest method of
determining their importance would be to modify the
number or nature of the bacteria, either by giving an-
tibiotics or by altering the bowel environment. At least
2 such studies of modest size are already under way,
one targeting patients with HF and raised plasma
concentrations of procalcitonin and treating themwith
metronidazole or ciproﬂoxacin and the other with a
fecal bulking agent (25). Should either approach prove
effective, large-scale studies should evaluate if “the
way to a man’s heart is truly through his stomach.”
Presumably, the results also might apply to women!
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Benjamin Dicken, Hull York Medical School, Depart-
ment of Cardiology, Hull and East Yorkshire Medical
Research and Teaching Centre, Castle Hill Hospital,
Cottingham, Kingston upon Hull HU16 5JQ, United
Kingdom. E-mail: benjamin.dicken@hey.nhs.uk.RE F E RENCE S1. Sandek A, Springer J, Habedank D, Brunkhorst F,
Anker SD. Procalcitonin-guided antibiotic treat-
ment in heart failure. Lancet 2004;363:1555.
2. Brunkhorst FM, Clark AL, Forycki ZF, Anker SD.
Pyrexia, procalcitonin, immune activation and sur-
vival in cardiogenic shock: the potential importance
ofbacterial translocation. Int JCardiol 1999;72:3–10.3. de Boer RA, van der Velde AR, Mueller C, et al.
Galectin-3: a modiﬁable risk factor in heart failure.
Cardiovasc Drugs Ther 2014;28:237–46.
4. Doehner W. A direct link between haemody-
namic failure and inﬂammatory activation in heart
failure: the simpliﬁed approach to heart failure and
to creation of life. Eur Heart J 2014;35:413–5.5. Damy T, Kallvikbacka-Bennett A, Zhang J, et al.
Does the physical examination still have a role in
patients with suspected heart failure? Eur J Heart
Fail 2011;13:1340–8.
6. Niebauer J, Volk H, KempM, et al. Endotoxin and
immune activation in chronic heart failure: a pro-
spective cohort study. Lancet 1999;353:1838–42.
J A C C V O L . 6 4 , N O . 1 1 , 2 0 1 4 Dicken and Cleland
S E P T E M B E R 1 6 , 2 0 1 4 : 1 1 0 3 – 5 Intestinal Blood Flow and Flora in Heart Failure
11057. Sandek A, Swidsinski A, Schroedl W, et al.
Intestinal blood ﬂow in patients with chronic heart
failure: a link with bacterial growth, gastrointes-
tinal symptoms, and cachexia. J Am Coll Cardiol
2014;64:1092–102.
8. Arutyunov G, Kostyukevich O, Serov R,
Rylova N, Bylova N. Collagen accumulation and
dysfunctional mucosal barrier of the small intes-
tine in patients with chronic heart failure. Int J
Cardiol 2008;125:240–5.
9. Bourantas CV, Loh HP, Sherwi N, et al.
Atherosclerotic disease of the abdominal aorta
and its branches: prognostic implications in
patients with heart failure. Heart Fail Rev 2012;17:
229–39.
10. Anker S, Sharma R. The syndrome of cardiac
cachexia. Int J Cardiol 2002;85:51–66.
11. Celik T, Iyisoy A, Yuksel U, Jata B. The small
intestine: a critical linkage in pathophysiology
of cardiac cachexia. Int J Cardiol 2010;143:
200–16.
12. Mancini D, Walter G, Reichek N. Contribution
of skeletal muscle atrophy to exercise intolerance
and altered muscle metabolism in heart failure.
Circulation 1992;85:1364–73.
13. Futter JE, Cleland JG, Clark AL. Body mass
indices and outcome in patients with chronic heart
failure. Eur J Heart Fail 2011;13:207–13.14. Doehner W. Critical appraisal of the obesity
paradox in cardiovascular disease: How to manage
patients with overweight in heart failure? Heart
Fail Rev 2014 Feb 20 [Epub ahead of print].
15. Lainscak M, von Haehling S, Doehner W,
Anker SD. The obesity paradox in chronic disease:
facts and numbers. J Cachexia Sarcopenia Muscle
2012;3(1):1–4.
16. Rienstra M, Damman K, Mulder BA, et al.
Beta-blockers and outcome in heart failure and
atrial ﬁbrillation: a meta-analysis. J Am Coll Car-
diol Heart Fail 2013;1:21–8.
17. O’Connor CM, Whellan DJ, Lee KL, et al.
Efﬁcacy and safety of exercise training in patients
with chronic heart failure: HF-ACTION randomized
controlled trial. JAMA 2009;301:1439–50.
18. Cleland JGF, Atkin SL. Thiazolidinediones,
deadly sins, surrogates and elephants. Lancet
2007;370:1103–4.
19. Mann D, McMurray J, Packer M, et al. Targeted
anticytokine therapy in patients with chronic heart
failure: results of the Randomized Etanercept
Worldwide Evaluation (RENEWAL). Circulation
2004;109:1594–602.
20. Chung ES, Packer M, Lo KH, et al. Randomized,
double-blind, placebo-controlled, pilot trial of
inﬂiximab, a chimeric monoclonal antibody to
tumor necrosis factor-alpha, in patients withmoderate-to-severe heart failure: results of the
Anti-TNF Therapy Against Congestive Heart Failure
(ATTACH) trial. Circulation 2003;107:3133–40.
21. Jain A, Singh JA. Harms of TNF inhibitors in
rheumatic diseases: a focused review of the liter-
ature. Immunotherapy 2013;5:265–99.
22. Grayston JT, Kronmal RA, Jackson LA, et al.
Azithromycin for the secondary prevention of
coronary events. N Engl J Med 2005;352:1637–45.
23. O’Connor CM, Dunne MW, Pfeffer MA, et al.
Azithromycin for the secondary prevention of
coronary heart disease events: the WIZARD study:
a randomized controlled trial. JAMA 2003;290:
1459–66.
24. Cannon CP, Braunwald E, McCabe CH, et al.
Antibiotic treatment of Chlamydia pneumoniae
after acute coronary syndrome. N Engl J Med
2005;352:1646–54.
25. Costanzo MR, Heywood JT, Massie BM, et al.
A double-blind, randomized, parallel, placebo-
controlled study examining the effect of cross-
linked polyelectrolyte in heart failure patients
with chronic kidney disease. Eur J Heart Fail 2012;
14:922–30.KEY WORDS bacteria, gastrointestinal
symptoms, heart failure, intestinal blood ﬂow
